Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 24 NET 17 Gastrointestinal 8 Tumor-Agnostic 1 Gynecologic 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1

Interventions

Temozolomide 623 Radiotherapy 411 Bevacizumab 257 Magnetic Resonance Spectroscopy 227 Cyclophosphamide 179 Radiosurgery 163 Carboplatin 160 Etoposide 132 Radiation 129 Vincristine 115 Irinotecan 115 Cisplatin 103 Filgrastim 100 Specimen Handling 90 Nivolumab 88 pembrolizumab 84 Surgical Procedures, Operative 83 Lomustine 83 Topotecan 73 Doxorubicin 61 Melphalan 59 Carmustine 57 Radiotherapy, Intensity-Modulated 56 sargramostim 53 Isotretinoin 53 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 51 Chemotherapy, Adjuvant 51 Blood Specimen Collection 51 Erlotinib Hydrochloride 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

lanreotide × CNS × Clear all

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡